Claro Advisors LLC Boosts Stake in Hologic, Inc. (NASDAQ:HOLX)

Claro Advisors LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 730.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,525 shares of the medical equipment provider's stock after acquiring an additional 24,210 shares during the quarter. Claro Advisors LLC's holdings in Hologic were worth $2,242,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in HOLX. Price T Rowe Associates Inc. MD boosted its stake in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider's stock worth $188,243,000 after purchasing an additional 450,190 shares during the last quarter. Black Creek Investment Management Inc. grew its holdings in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock worth $173,669,000 after buying an additional 885,524 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Hologic by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock valued at $172,780,000 after buying an additional 124,739 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider's stock worth $168,666,000 after acquiring an additional 87,176 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOLX has been the subject of a number of recent research reports. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Citigroup downgraded Hologic from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upped their target price on Hologic from $91.00 to $95.00 and gave the company an "overweight" rating in a report on Tuesday, July 30th. StockNews.com lowered Hologic from a "strong-buy" rating to a "buy" rating in a report on Friday, September 27th. Finally, Stephens reissued an "overweight" rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $87.50.

Hologic Trading Up 1.4 %

NASDAQ HOLX traded up $1.10 on Friday, reaching $81.57. The stock had a trading volume of 1,085,604 shares, compared to its average volume of 1,587,194. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a fifty day moving average price of $80.94 and a two-hundred day moving average price of $77.73. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67. The firm has a market capitalization of $19.04 billion, a price-to-earnings ratio of 41.62, a P/E/G ratio of 2.89 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the business earned $0.93 EPS. The company's quarterly revenue was up 2.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the business's stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.75% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.